Outcome and genetic analysis of patients affected by retinal capillary hemangioblastoma in von Hippel Lindau syndrome.
Journal
Molecular vision
ISSN: 1090-0535
Titre abrégé: Mol Vis
Pays: United States
ID NLM: 9605351
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
03
2021
accepted:
31
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
14
1
2022
Statut:
epublish
Résumé
To describe genetic analysis, treatment results, and complications of patients affected by retinal capillary hemangioblastoma (RCH) in von Hippel Lindau (VHL) syndrome. We collected 17 patients with VHL syndrome, who underwent a molecular test and an ophthalmic evaluation at the Eye Clinic of the University Hospital of Florence from January 2005 to February 2020. We focused on eyes showing RCHs examined using color fundus photographs, fluorescein angiography, and optical coherence tomography. Eight eyes of six patients (6/17; 35%) showed RCHs at the fundoscopic examination. All RCHs were treated with laser therapy. Three eyes underwent episcleral surgery, one eye showing vitreous hemorrhage received three intravitreal (IV) anti-VEGF injections and three cryotherapy procedures, and one eye underwent vitrectomy. In patients with RCHs, five were characterized by a truncating mutation of the VHL protein, and one patient showed a missense mutation. We have reported two VHL mutations not reported in literature. Patients with multiple RCHs, who developed RCH secondary effects, showed truncating mutations of the VHL protein. We recommend early screening and close monitoring, especially if RCHs are detected at presentation, for every patient with VHL syndrome independently of the results of the molecular test for a missense or a truncating mutation in
Substances chimiques
Von Hippel-Lindau Tumor Suppressor Protein
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
542-554Informations de copyright
Copyright © 2021 Molecular Vision.
Références
Lancet. 2003 Jun 14;361(9374):2059-67
pubmed: 12814730
Science. 1993 May 28;260(5112):1317-20
pubmed: 8493574
Surv Ophthalmol. 2001 Sep-Oct;46(2):117-42
pubmed: 11578646
Q J Med. 1990 Nov;77(283):1151-63
pubmed: 2274658
Eur J Med Res. 2000 Feb 28;5(2):47-58
pubmed: 10720563
Ophthalmology. 2011 Jan;118(1):142-9
pubmed: 20801520
Acta Ophthalmol. 2020 Jan 30;:
pubmed: 32003155
Am J Hum Genet. 2000 Jan;66(1):84-91
pubmed: 10631138
Hum Mol Genet. 1995 Nov;4(11):2139-43
pubmed: 8589692
Retina. 2017 Apr;37(4):782-788
pubmed: 27533771
Ophthalmic Genet. 2014 Jun;35(2):91-106
pubmed: 24555745
Mol Cell. 2006 May 5;22(3):395-405
pubmed: 16678111
Arch Ophthalmol. 1995 Feb;113(2):143-4
pubmed: 7864744
Retina. 2018 Apr;38(4):748-754
pubmed: 28368975
Arch Ophthalmol. 2007 Feb;125(2):239-45
pubmed: 17296901
Retina. 1986 Winter;6(4):253-9
pubmed: 3554423
Retin Cases Brief Rep. 2016 Spring;10(2):145-50
pubmed: 26421964
Urology. 2014 Mar;83(3):675.e1-5
pubmed: 24581539
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
pubmed: 5279523
Ophthalmology. 2002 Oct;109(10):1799-806
pubmed: 12359597
Ophthalmology. 2006 Aug;113(8):1418-24
pubmed: 16769118
Graefes Arch Clin Exp Ophthalmol. 2004 Oct;242(10):881-6
pubmed: 15052488
Retina. 2019 Dec;39(12):2254-2263
pubmed: 31259811
Arch Ophthalmol. 2008 May;126(5):637-43
pubmed: 18474773
Ophthalmol Retina. 2017 Jan - Feb;1(1):59-67
pubmed: 31047395
Clin Endocrinol (Oxf). 2008 May;68(5):762-8
pubmed: 18031321
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3067-74
pubmed: 12202531
Am J Ophthalmol. 2015 Jul;160(1):107-13.e1
pubmed: 25892126